Last updated: March 2026
DMZ (dimethazine / dymethazine) is an oral designer steroid consisting of two Superdrol (methasterone) molecules linked by an azine bond. A prodrug cleaved in vivo to release methasterone, it was sold as a "legal" prohormone until DASCA 2014. Extremely hepatotoxic with virtually no clinical data — liver support is considered essential, not optional.
DMZ's mechanism is unusual: it's a prodrug that must be chemically broken down before it becomes pharmacologically active. Once cleaved, it acts identically to Superdrol — with the same effects and the same severe hepatotoxicity.
DMZ's defining structural feature is the azine bond (-N=N-) linking two methasterone molecules. This bond is cleaved by stomach acid and hydrolytic enzymes in the gastrointestinal tract, releasing two molecules of methasterone (Superdrol) per molecule of DMZ. This prodrug mechanism was originally exploited to classify DMZ as a "different" compound from controlled methasterone, allowing legal supplement sales. Once cleaved, there is no pharmacological difference from taking Superdrol directly.
Methasterone (the active compound released by DMZ) is 17α-alkylated, which enables oral bioavailability but forces the liver to metabolize the compound through cytochrome P450 pathways that generate oxidative stress. DMZ is considered among the most hepatotoxic oral compounds in community use because: (1) it releases two methasterone molecules per DMZ molecule, and (2) the prodrug conversion itself may place additional metabolic burden on the liver. Cholestasis, elevated transaminases, and hepatocellular stress are consistent findings in community bloodwork.
Methasterone (released from DMZ cleavage) binds androgen receptors with high affinity. It does not aromatize to estradiol, producing the characteristically dry, hard muscle appearance without water retention. Community reports consistently describe DMZ gains as dry and strength-focused. The lack of estrogenic activity means no gynecomastia from the compound itself, but also removes estrogen's cardioprotective effects, worsening the lipid profile impact significantly.
Like all androgenic compounds, DMZ (via released methasterone) suppresses the hypothalamic-pituitary-testicular axis through negative feedback. GnRH pulsatility is reduced, LH and FSH secretion drops, and Leydig cell testosterone production ceases during the cycle. Recovery of the HPTA after cycle completion requires post-cycle therapy (PCT) with selective estrogen receptor modulators (SERMs) like tamoxifen or clomiphene. HPTA recovery is considered non-negotiable in harm-reduction practice after any DMZ cycle.
No human clinical trials exist for DMZ. Data below combines community bloodwork reports, anecdotal observations, and in vitro structural analysis of methasterone (the active compound). Source quality is explicitly noted.
Liver protection and monitoring are non-negotiable with DMZ. These are the harm-reduction essentials — not optional purchases.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and harm-reduction purposes only. DMZ (dimethazine) is a Schedule III controlled substance in the United States under the Designer Anabolic Steroid Control Act (DASCA) of 2014. Possession, sale, or distribution without a valid prescription is a federal crime. No human clinical trials exist for dimethazine specifically. All human data is derived from anecdotal community reports and should not be interpreted as established medical fact. This content does not constitute medical advice. Always consult a licensed physician before using any anabolic agent.